HROW Stock Forecast & Price Target

Harrow Inc. is positioned to benefit from the expanding market for biosimilars, with significant market share exceeding 40% in certain therapeutic categories, aligning with healthcare cost reduction goals. The company's VEVYE product reported a notable 22% quarter-over-quarter revenue increase, reaching $22.6 million in 3Q25 and capturing a 10.5% share of the national dry eye disease market. Strong prescription growth momentum and projections for a quarterly revenue run rate exceeding $250 million by 4Q27 further bolster Harrow's long-term revenue and margin expansion outlook.

Harrow Inc faces significant challenges that contribute to a negative outlook for its stock, primarily linked to the potential failure of its spinout products to achieve favorable clinical data or secure regulatory approvals, which could adversely impact valuation. The company is also exposed to risks including lower-than-expected market uptake of its products, difficulties in developing its pipeline, and potential dilution of shares due to necessary capital raises, all of which could lead to a diminished ability to service its outstanding debt. Furthermore, Harrow's limited resources may force it to curtail aggressive sales and marketing initiatives, hindering growth prospects and operational effectiveness in a competitive eyecare market.